

## Supporting Information

### **A rapid, multiplexed kinase activity assay using 8-plex iTRAQ**

#### **labeling, SPE, and MALDI-TOF/TOF MS**

Yu-Ching Liu<sup>a</sup>, Fuu-Jen Tsai<sup>b, c, d</sup>, Chao-Jung Chen<sup>a, e\*</sup>

<sup>a</sup> Graduate Institute of Integrated Medicine, China Medical University, Taichung 40402, Taiwan

<sup>b</sup> Human Genetic Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan

<sup>c</sup> Department of Health and Nutrition Biotechnology, Asia University, Taichung 41354, Taiwan

<sup>d</sup> School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan


<sup>e</sup> Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan

**Supplementary Figure 1.** Evaluation of protein effect for phosphopeptides enrichment by TiO<sub>2</sub> plate.


**Supplementary Figure 2.** Solvent precipitation effect on phosphopeptide purification.

**Supplementary Figure 3.** MALDI-TOF MS spectra of PS1-PS6 after multikinase reaction.


**Supplementary Figure 4.** MALDI-TOF/TOF MS spectra of mass tag signals of PS1-PS6 after multikinase reaction with different protein amount and incubation times.




**Supplementary Figure 1. Evaluation of protein effect for phosphopeptides enrichment by TiO<sub>2</sub> plate.** (a) 2 pmol phosphopeptides and (b) the mixture of phosphopeptides (2 pmol) and proteins (20 µg) were applied to TiO<sub>2</sub> plate. Step 1: samples were dissolved in loading buffer (80% ACN/ 2% TFA/ 20 mg mL<sup>-1</sup> of DHB) were applied to TiO<sub>2</sub> plate. Step 2: the spots were washed with the 80% ACN/2% TFA solution. Step 3: phosphopeptides were eluted with 0.05% NH<sub>4</sub>OH and deposited on PDMS plate. Step 4: DHB/PA matrix solution (2 mg/mL DHB in 25% ACN and 1% PA) were applied to analysts. (c) MALDI-TOF MS analysis of the two phosphopeptides VNQIG(pT)LSESIK (1368.68 m/z) and VNQIGTL(pS)E(pS)IK (1448.64 m/z) without/with protein after TiO<sub>2</sub> plate enrichment. The phosphopeptide signals were normalized to the internal standard of KFTRQTPVDSPIR (1578.84 m/z, 300 fmole).



**Supplementary Figure 2. Solvent precipitation effect on phosphopeptide purification.** The solvent (ACN/MeOH, 50%/50%)/sample volume ratio of 2, 4, 6 and 8 folds were used for precipitating proteins in the samples followed by TiO<sub>2</sub> plate purification and MALDI-TOF MS analysis. (a) White protein aggregates on TiO<sub>2</sub> plate were significantly observed using solvent/sample volume ratio from 2-8 folds. (b) The eluent analyte from the TiO<sub>2</sub> plate were deposited on a PDMS-coated MALDI target. (c) The sample/DHB matrix co-crystals on a PDMS-coated MALDI target. The control sample had phosphopeptides without adding proteins and solvent precipitation.



**Supplementary Figure 3. MALDI-TOF MS spectra of PS1-PS6 after multikinase reaction.** The phosphorylated iTRAQ labeled peptide substrates are the major peaks with some minor signals of truncated and metastable peaks. ▲: truncated form of PS3 missing ER. ●: truncated form of PS3 missing R. ○: metastable ion after loss of 86 Da of the phosphopeptide peak.



**Supplementary Figure 4. MALDI-TOF/TOF MS spectra of mass tag signals of PS1-PS6 after multikinase reaction with different protein amount and incubation times.** The reporter ion signals of phosphorylated peptide substrates from (a) different protein amounts (113 and 114: 5  $\mu$ g ; 115 and 116:10  $\mu$ g; 117 and 118: 20  $\mu$ g; 119 and 121: 40  $\mu$ g) and (b) incubation times (113 and 114: 30 min; 115 and 116: 60 min; 117 and 118: 90 min, 119 and 121: 120 min).